0NX.F VOXEL SA ZY 1
- Market cap
- EUR 358M
- P/E
- 12.5x
- P/B
- 3.69x
- ROE
- 29.3%
- Dividend yield
- 1.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0NX.F undervalued?
Graham number0NX.F trades 43.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VOXEL SA ZY 1 fundamental analysis
No fundamental analysis for VOXEL SA ZY 1 yet.
VOXEL SA ZY 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VOXEL SA ZY 1
Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.
Full company profileVOXEL SA ZY 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VOXEL SA ZY 1 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 443M | 361M | 424M | 508M | 584M | 684M |
| Gross Profit | 128M | 107M | 140M | 155M | 168M | 207M |
| Operating Income | 105M | 86.6M | 118M | 130M | 134M | 173M |
| EBITDA | - | 118M | 151M | 176M | 189M | 215M |
| Net Income | 70.5M | 44.4M | 74.2M | 96.5M | 98.5M | 129M |
| EPS | 6.72 | 4.23 | 7.07 | 9.18 | 9.38 | 12 |
| Balance Sheet | ||||||
| Total Assets | 495M | 467M | 529M | 639M | 707M | 759M |
| Total Liabilities | 265M | 223M | 234M | 273M | 291M | 311M |
| Shareholders' Equity | 229M | 242M | 293M | 361M | 409M | 440M |
| Cash & Short-term Investments | 54.1M | 33.2M | 64.1M | 52.9M | 13.0M | 34.9M |
| Cash Flow | ||||||
| Operating Cash Flow | 106M | 96.2M | 129M | 122M | 117M | 163M |
| Capital Expenditure | 31.7M | 31.0M | 44.3M | 70.6M | 75.8M | 15.8M |
| Free Cash Flow | 74.7M | 65.2M | 84.8M | 51.7M | 40.9M | 147M |
| Ratios | ||||||
| ROE | 30.8% | 18.4% | 25.3% | 26.8% | 24.1% | 29.3% |
| ROA | 14.3% | 9.5% | 14.0% | 15.1% | 13.9% | 17.0% |
| Net Profit Margin | 15.9% | 12.3% | 17.5% | 19.0% | 16.9% | 18.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VOXEL SA ZY 1 dividends
- Dividend yield
- 1.68%
- Forward dividend
- 0.57 EUR
- Payout ratio
- 48.4%
- Ex-dividend date
- Sep 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 47.7M | 4.54 | 48.4% |
| 2024 | PLN 34.6M | 3.29 | 35.8% |
| 2023 | PLN 15.1M | 1.44 | 20.4% |
| 2022 | PLN 32.2M | 3.07 | 72.6% |
| 2021 | PLN 21.6M | 2.06 | 30.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns VOXEL SA ZY 1
- Insiders 37.43%
- Institutions 31.89%
- Public & others 30.68%
- Shares outstanding 10.5M
- Free float 5.04M
VOXEL SA ZY 1 company profile
- Company name
- VOXEL SA ZY 1
- Ticker
- 0NX.F
- ISIN
- PLVOXEL00014
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 356
- Fiscal year end
- December
- Address
- ul. Wielicka 265, Kraków, Poland, 30-663
- Phone
- 48 12 651 1302
- Website
- voxel.pl
About VOXEL SA ZY 1
Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.
VOXEL SA ZY 1 management
2- Mr. Jaroslaw FurdalChairman of the Management Board
- Mr. Grzegorz RutkowskiVice Chairman of the Management Board